Pattern of primary tuberculosis drug resistance and associated risk factors at Dubai health authority in Dubai

Habous, Maya; Elimam, Maimona; AlDabal, Laila; Chidambaran, Bindu; AlDeesi, Zulfa O.

doi:10.4103/ijmy.ijmy_170_20

Cited by 15 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the same study, resistance to at least one or more first line anti-TB medicine was 17.3% which was higher than 6% in Oman but lower than 32.4% in Jordan ( 43 ). The study also confirmed that isoniazid resistance was more prevalent in Dubai ( 42 ). To build on previous UAE studies, we report for the first time MTB-complex AMR trends across the UAE over a 12-year period (2010–2021) collected through a National Surveillance Program.…”

Section: Introductionsupporting

confidence: 74%

“…Other studies in the UAE have reported that 8–10% of Emirati medical students and 0.5% of Emirati children have LTBI following a TB interferon gamma release assay positive result (IGRA) ( 40 , 41 ). A recent study published in 2020 found that among 1,116 newly identified TB patients within the Dubai Health Authority during 2016–2019, 6.9% of cases had MDR TB ( 42 ). In the same study, resistance to at least one or more first line anti-TB medicine was 17.3% which was higher than 6% in Oman but lower than 32.4% in Jordan ( 43 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiology and antimicrobial resistance of Mycobacterium spp. in the United Arab Emirates: a retrospective analysis of 12 years of national antimicrobial resistance surveillance data

Thomsen,

Abdulrazzaq,

Nyasulu

et al. 2024

Front. Public Health

Self Cite

View full text Add to dashboard Cite

IntroductionThe Eastern Mediterranean Regional Office (EMRO) region accounts for almost 8% of all global Mycobacterium tuberculosis (TB) cases, with TB incidence rates ranging from 1 per 100,000 per year in the United Arab Emirates (UAE) to 204 per 100,000 in Djibouti. The national surveillance data from the Middle East and North Africa (MENA) region on the epidemiology and antimicrobial resistance trends of TB, including MDR-TB remains scarce.MethodsA retrospective 12-year analysis of N = 8,086 non-duplicate diagnostic Mycobacterium tuberculosis complex (MTB complex) isolates from the UAE was conducted. Data were generated through routine patient care during the 2010–2021 years, collected by trained personnel and reported by participating surveillance sites to the UAE National Antimicrobial Resistance (AMR) Surveillance program. Data analysis was conducted with WHONET, a windows-based microbiology laboratory database management software developed by the World Health Organization Collaborating Center for Surveillance of Antimicrobial Resistance, Boston, United States (https://whonet.org/).ResultsA total of 8,086 MTB-complex isolates were analyzed. MTB-complex was primarily isolated from respiratory samples (sputum 80.1%, broncho-alveolar lavage 4.6%, pleural fluid 4.1%). Inpatients accounted for 63.2%, including 1.3% from ICU. Nationality was known for 84.3% of patients, including 3.8% Emiratis. Of UAE non-nationals, 80.5% were from 110 countries, most of which were Asian countries. India accounted for 20.8%, Pakistan 13.6%, Philippines 12.7%, and Bangladesh 7.8%. Rifampicin-resistant MTB-complex isolates (RR-TB) were found in 2.8% of the isolates, resistance to isoniazid, streptomycin, pyrazinamide, and ethambutol, was 8.9, 6.9, 3.4 and 0.4%, respectively. A slightly increasing trend of resistance among MTB-complex was observed for rifampicin from 2.5% (2010) to 2.8% (2021).ConclusionInfections due to MTB-complex are relatively uncommon in the United Arab Emirates compared to other countries in the MENA region. Most TB patients in the UAE are of Asian origin, mainly from countries with a high prevalence of TB. Resistance to first line anti-tuberculous drugs is generally low, however increasing trends for MDR-TB mainly rifampicin linked resistance is a major concern. MDR-TB was not associated with a higher mortality, admission to ICU, or increased length of hospitalization as compared to non-MDR-TB.

show abstract

Section: Introductionsupporting

confidence: 74%

Section: Introductionmentioning

confidence: 99%

Epidemiology and antimicrobial resistance of Mycobacterium spp. in the United Arab Emirates: a retrospective analysis of 12 years of national antimicrobial resistance surveillance data

Thomsen,

Abdulrazzaq,

Nyasulu

et al. 2024

Front. Public Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…The rate of primary DR-TB was 24.5% in this study, higher than the result from Mexico (18.3%) [12] and Shandong, China (18.95%). [11] Furthermore, the rates of MDR-TB and XDR-TB among newly diagnosed TB cases were 9.8% and 3%, respectively, which were higher than other studies in China (5.7% and 0.4%, respectively) [13] and Dubai (4.5%% and 0.09%, respectively), [14] but lower than the results from Amhara Region of Ethiopia (RR/MDR-TB: 15.69%), [15] South Africa (RR/MDR-TB: 49%), [16] and the Vladimir Region of Russia (RR/MDR-TB: 73.3%). [17] It should be noted that the incidence of TB is higher in the western region than in the eastern and central regions of China.…”

Section: Discussionmentioning

confidence: 86%

Patterns and trends of primary drug-resistant tuberculosis in Chongqing, China, from 2012 to 2020

et al. 2023

View full text Add to dashboard Cite

Primary drug-resistant tuberculosis (DR-TB) contributes significantly to the global TB epidemic, particularly in countries with high TB burdens. This study aimed to investigate the characteristics of primary DR-TB prevalence in Chongqing, China, from 2012 to 2020. A total of 4546 newly diagnosed and 2769 relapse TB patients admitted to the hospital from 2012 to 2020 were included. Categorical variables were compared using Pearson chi-square test or Fisher exact test, as appropriate. Logistic regression analysis was performed to determine factors associated with primary DR-TB. The rate of primary DR-TB was 24.5%, whereas that of acquired DR-TB was 67.8%. Among newly diagnosed TB cases, the percentage of DR-TB (from 48.9 to 44.2%), monoresistant TB (from 11.8 to 9.7%), multidrug-resistant TB (MDR-TB; from 25.3 to 6.9%), and pre-extensive drug-resistant TB (from 13.7 to 5.8%) showed a decreasing trend from 2012 to 2020. Age from 15 to 64 years was a risk factor for the development of primary DR-TB (15-44 years: adjusted odds ratio = 2.227, 95% confidence interval: 1.053-4.710; 45-64 years: adjusted odds ratio = 2.223, 95% confidence interval: 1.048-4.717). The rates of primary DR-TB (P = .041) and MDR-TB (P = .007) were significantly higher in the age group of 15 to 64 years than in the age groups of ≤14 years and ≥65 years. Noticeably, rising trends of primary DR-TB (from 0 to 27.3%) and MDR-TB (from 0 to 9.1%) in the population of ≤14 years were observed from 2012 to 2020. Although the rate of primary DR-TB showed a downward trend, a rising drug-resistance rate among some particular subgroups was still observed. Further control of primary DR-TB should focus more on TB patients aged 15 to 64 years. Abbreviations: aOR = adjusted odds ratio, DR = drug-resistant, DST = drug susceptibility testing, INH = isoniazid, MDR = multidrug-resistant, MR = mono-resistant, PDR = polydrug-resistant, pre-XDR = pre-extensive drug-resistant, RFP = rifampicin, RR = rifampicin-resistant, TB = tuberculosis.

show abstract

“…A mobilidade populacional, incluindo a migração interna ou internacional, pode contribuir para a influência da tuberculose. Pessoas que viajam para áreas com alta incidência da doença ou que vivem em condições de deslocamento, como campos de refugiados, estão mais expostas ao risco de infecção (AYELIGN et al, 2019;HABOUS et al, 2020).…”

Section: Fatores De Risco Para a Tuberculoseunclassified

“…É importante destacar que esses fatores de risco não garantem necessariamente que uma pessoa desenvolverá a tuberculose, mas aumentará a probabilidade. A conscientização sobre esses fatores é fundamental para identificar grupos de alto risco, implementar medidas de prevenção e garantir o diagnóstico e tratamento adequado para aqueles que contraem a doença (HABOUS et al, 2020).…”

Section: Fatores De Risco Para a Tuberculoseunclassified

Paciente Com Insuficiência Mitral Decorrido Por Uma Cardiomegalia Chagásica: Relato De Caso

Oliveira¹,

Gonçalves²,

Pinheiro³

et al. 2023

Doenças Infecciosas E Parasitárias

View full text Add to dashboard Cite

Os autores desta obra assumem publicamente a responsabilidade pelo seu conteúdo, garantindo que o mesmo é de autoria própria, original e livre de plágio acadêmico. Os autores declaram, ainda, que o conteúdo não infringe nenhum direito de propriedade intelectual de terceiros e que não há nenhuma irregularidade que comprometa a integridade da obra. Os autores assumem integral responsabilidade diante de terceiros, quer de natureza moral ou patrimonial, em razão do conteúdo desta obra. Esta declaração tem por objetivo garantir a transparência e a ética na produção e divulgação do artigo. Cumpre esclarecer que o conteúdo do artigo é de responsabilidade exclusiva dos autores, não refletindo, necessariamente, a opinião da editora ou do conselho editorial.

show abstract

Pattern of primary tuberculosis drug resistance and associated risk factors at Dubai health authority in Dubai

Cited by 15 publications

References 0 publications

Epidemiology and antimicrobial resistance of Mycobacterium spp. in the United Arab Emirates: a retrospective analysis of 12 years of national antimicrobial resistance surveillance data

Epidemiology and antimicrobial resistance of Mycobacterium spp. in the United Arab Emirates: a retrospective analysis of 12 years of national antimicrobial resistance surveillance data

Patterns and trends of primary drug-resistant tuberculosis in Chongqing, China, from 2012 to 2020

Paciente Com Insuficiência Mitral Decorrido Por Uma Cardiomegalia Chagásica: Relato De Caso

Contact Info

Product

Resources

About